Our Members: Global Community Evaluating Test Utilization
To further appropriate test utilization in the laboratory, ASCP joined the American Board of Internal Medicine Foundation’s “Choosing Wisely” campaign to start physicians, patients, and other healthcare stakeholders thinking and talking about the overuse or misuse of medical tests and procedures that provide little benefit and, in some instances, cause harm to patients.
Writing about reducing healthcare costs through appropriate test utilization, ASCP President C. Bruce Alexander, MD, FASCP, suggested it is time to “create a new paradigm for cooperation between the clinicians who decide what tests to order and the laboratory staff.”
While ASCP clearly supports the idea of widespread adoption of electronic health records (EHRs), it has steadfastly worked to ensure that pathologists and laboratory professionals are appropriately recognized and reimbursed in patients’ EHRs—a protection that is threatened under the pending implementation of Stage 2 of the U.S. Centers for Medicare & Medicaid Services (CMS) EHR Incentive Programs.
ASCP initially alerted CMS that the current Meaningful Use reporting requirements cannot be satisfied by pathologists, and, therefore, it is inappropriate for CMS to subject them to reimbursement penalties for failure to meet reporting requirements they are unable to satisfy. ASCP then formally endorsed a bipartisan legislative proposal (HR4066) to reform the way the Medicare Meaningful Use standards treat pathologists and will continue to resolutely promote this endeavor.